Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
Niche launches in the US drive numbers; future pipeline key for sustainability Earning momentum strong till FY26; apparent slowdown in FY27 but pipeline buildup to continue- Strong growth was attributable US launches under exclusivity (gMyrbetriq, gTolvaptan and gSpiriva) and launches across regions. India was impacted due to lower tender sales in Institutional business. The company has maintained the strong EBITDA margins trajectory mainly driven by strong GPM performance. The...
Well poised to see significant recovery in explosives & exports/overseas segment: With market leading share of ~25% in domestic industrial explosives market, we believe that company is well poised to grow steadily led by healthy demand prospects from segments like mining, housing and infrastructure. Though domestic explosives segment remained muted during the quarter, we expect recovery going ahead led by healthy demand from housing, infra and mining sectors. With an order backlog of 1600+ crore in explosives and stable raw material prices, we expect ~14%...
Standalone EBITDA increased 7.8% YoY to Rs. 4,426cr as production costs fell, byproducts' realisations went up and the prices of input commodities softened. Reported PAT increased 14.5% YoY to Rs. 2,632cr owing to a growth in improved EBITDA and a fall in finance costs. HZL's revenue growth in the quarter was partially offset by a decline in production due to delay in commissioning of Roaster 6, which has impacted the availability of Calcine *over or under performance to benchmark index affecting company's production. Strong private consumption, capital expenditure and favourable government policies have helped create a positive demand environment that is...
In H1FY26, VNB rose 14% YoY to Rs. 2,750cr, with VNB margin at 27.8% (vs 26.8% in H1FY25), led by steady protection growth, favourable product mix and stronger 13th-month persistency at 87.1% vs 86.4%, reflecting improved policy...
Play on India’s solar scale-up; indigenization of clean power generation: WEL encapsulates the India module story, with national installed solar capacity set to rise from 100GW in 1QFY26 to 160GW by FY28.
concepts. Its primary customer propositions include Westside, one of India's leading chains of fashion retail stores, Zudio, a one stop destination for great fashion at great value and Trent Hypermarket, which operates in the competitive...
Bajaj Auto’s (BJAUT) Q2FY26 operational performance was broadly in line with our estimate. Domestic 2W industry growth is expected to pick-up pace (~6-8% volume growth) going ahead led by the benefit of GST rationalisation and strong festive season.
*over or under performance to benchmark index In Q2FY26, ITC's standalone revenue declined 2.7% YoY to Rs. 19,148cr, due to a sharp drop in agri business exports. However, core segmentscigarettes and...
Hindalco (HNDL)’s Q2FY26 EBITDA, at INR 89.7bn, was 5% better than our estimates driven by Novelis’ stronger performance, while HNDL’s domestic business aligned with our estimates.
Lupin delivered a beat of 9.5%/26.3%/21.8% in revenue/EBITDA/PAT vs our estimates in Q2FY26, driven by exclusive products like Tolvaptan and Mirabegron.
Apollo Hospitals’ (Apollo) hospital biz grew slower at ~9% YoY in Q2FY26, though in line with our expectations. On a high base, occupancy declined to 69% in Q2 while lower international patients and few medical admissions also had an impact.
Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.
Torrent Pharma’s (Torrent) Q2FY26 result was in line with our expectations. While Torrent continues to grow at a faster pace in India (+11.5%), its growth in the US (+15.9%) was driven by new launches like gEntresto; stability in currency has sustained its growth in Brazil (+20.9%).
Power Finance Corporation (PFC)’s 2QFY26 PAT grew ~2% YoY to INR44.6b (~17% miss). PAT in 1HFY26 grew 11% YoY, and we expect PAT in 2HFY26 to grow by 10% YoY.
